Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-interventional Cohort Study of Patients Previously Untreated or First-generation BTKi Intolerant With Chronic Lymphocytic Leukemia Describing the First-line Use of Acalabrutinib and Its Real-world Outcomes in Spain: the PICAROS Study

NCT05999877 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05999877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05999877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-interventional Cohort Study of Patients Previously Untreated or First-generation BTKi Intolerant With Chronic Lymphocytic Leukemia Describing the First-line Use of Acalabrutinib and Its Real-world Outcomes in Spain: the PICAROS Study
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
July 11, 2023
Completion date
March 31, 2029
Enrollment
315 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia